Decreasing Amphetamine-Induced Dopamine Release by Acute Phenylalanine/Tyrosine Depletion: a PET/ [11C]Raclopride Study in Healthy Men

Total Page:16

File Type:pdf, Size:1020Kb

Decreasing Amphetamine-Induced Dopamine Release by Acute Phenylalanine/Tyrosine Depletion: a PET/ [11C]Raclopride Study in Healthy Men Neuropsychopharmacology (2004) 29, 427–432 & 2004 Nature Publishing Group All rights reserved 0893-133X/04 $25.00 www.neuropsychopharmacology.org Decreasing Amphetamine-Induced Dopamine Release by Acute Phenylalanine/Tyrosine Depletion: A PET/ [11C]Raclopride Study in Healthy Men 1,2, 2 2 1 3 2 Marco Leyton *, Alain Dagher , Isabelle Boileau , Kevin Casey , Glen B Baker , Mirko Diksic , Roger 2 1 1,2 Gunn , Simon N Young and Chawki Benkelfat 1 2 Department of Psychiatry, McGill University, Montre´al, Que´bec, Canada; Department of Neurology & Neurosurgery, McGill University, 3 Montre´al, Que´bec, Canada; Department of Psychiatry, Mackenzie Centre, University of Alberta, Edmonton, Alberta, Canada Acute phenylalanine/tyrosine depletion (APTD) has been proposed as a new method to decrease catecholamine neurotransmission safely, rapidly, and transiently. Validation studies in animals are encouraging, but direct evidence in human brain is lacking. In the present study, we tested the hypothesis that APTD would reduce stimulated dopamine (DA) release, as assessed by positron emission 11 tomography (PET) and changes in [ C]raclopride binding potential (BP), a measure of DA D2/D3 receptor availability. Eight healthy men 11 received two PET scans, both following d-amphetamine, 0.3 mg/kg, p.o., an oral dose known to decrease [ C]raclopride BP in ventral striatum. On the morning before each scan, subjects ingested, in counter-balanced order, an amino-acid mixture deficient in the catecholamine precursors, phenylalanine, and tyrosine, or a nutritionally balanced mixture. Brain parametric images were generated by calculating [11C]raclopride BP at each voxel. BP values were extracted from the t-map (threshold: t ¼ 4.2, equivalent to p 0.05, o Bonferroni corrected) and a priori identified regions of interest from each individual’s coregistered magnetic resonance images. Both 11 receptor parametric mapping and region of interest analyses indicated that [ C]raclopride binding was significantly different on the two 11 test days in the ventral striatum (peak t ¼ 6.31; x ¼À25, y ¼À8, and z ¼ 0.1). In the t-map defined cluster, [ C]raclopride BP values were 11.8 7 11.9% higher during the APTD session (po0.05). The reduction in d-amphetamine-induced DA release exhibited a linear association with the reduction in plasma tyrosine levels (r ¼À0.82, po0.05). Together, the results provide the first direct evidence that APTD decreases stimulated DA release in human brain. APTD may be a suitable new tool for human neuropsychopharmacology research. Neuropsychopharmacology (2004) 29, 427–432, advance online publication, 29 October 2003; doi:10.1038/sj.npp.1300328 Keywords: dopamine; [11C]raclopride; catecholamine; tyrosine depletion INTRODUCTION Rot et al, 2003), amphetamine-induced changes in impulse control (Rot et al, 2003), alcohol self-administration in The acute phenylalanine/tyrosine depletion (APTD) method social drinkers (Leyton et al, 2000a), withdrawal-related was recently developed as a new tool to investigate the craving in nicotine-dependent smokers (Casey et al, 2002), effects of catecholamine neurotransmission in humans and mood both in healthy subjects (Leyton et al, 2000b; (Moja et al, 1996; Sheehan et al, 1996; Leyton et al, Harmer et al, 2001) and manic patients (McTavish et al, 2000b). Initial studies suggest that APTD decreases 2001). subjective effects of amphetamine (McTavish et al, 1999b; An assumption in these studies is that APTD is inducing functionally significant decreases in brain catecholamine A preliminary report based on this study was presented at the Annual synthesis. Animal studies support this possibility. APTD Meeting of the American College of Neuropsychopharmacology, San decreases post-mortem tissue concentrations of the dopa- Juan, Puerto Rico, December 8–12, 2002 mine (DA) metabolites homovanillic acid (HVA) and *Correspondence: M Leyton, Department of Psychiatry, McGill dihydroxyphenylacetic acid (Biggio et al, 1976), ampheta- University, 1033 Pine Avenue West, Montreal, Quebec, Canada mine-induced DA release (McTavish et al, 1999a), and H3A 1A1, Tel: +1-514-398-5804, Fax: +1-514-398-4866, E-mail: [email protected] cerebrospinal fluid (CSF) concentrations of HVA and the Received 05 April 2003; revised 27 August 2003; accepted 02 norepinephrine (NE) metabolite, 3-methoxy-4-hydroxyphe- September 2003 nethyleneglycol (Palmour et al, 1998). In humans, though, Online publication: 3 September 2003 at http://www.acnp.org/ the evidence remains circumstantial: APTD is reported to citations/Npp09030303152/default.pdf decrease blood pressure (Moja et al, 1996) and increase APTD decreases DA release M Leyton et al 428 circulating levels of prolactin (Harmer et al, 2001), but approximately 1.5 h before tracer injection (mean 7 SD, direct evidence of decreased catecholamine transmission in 1.4 7 0.5 h) and 3.5 h after administration of the AA brain is lacking. mixture (3.6 7 0.5 h). In the present study, we sought to assess whether APTD Subjects underwent two scans on separate days between would reduce stimulated DA release in human striatum, as 1400 and 1700 on a Siemens ECAT HR+ PET scanner measured by positron emission tomography (PET) and (maximum resolution 4.1  4.1  4.5 mm3, full-width half- [11C]raclopride. Healthy subjects were administered a maximum in center of field of view in air) with lead septa nutritionally balanced (BAL) amino-acid (AA) mixture removed. At 1 h before tracer injection, a catheter was containing the catecholamine precursors, phenylalanine inserted into the subject’s antecubital vein. Immediately and tyrosine, and, on a separate day, the phenylalanine/ before tracer injection, transmission scans were performed tyrosine-deficient mixture. Ingestion of the latter mixture using 68Ga for attenuation correction. Approximately, induces protein synthesis, leading to a transient reduction 10 mCi of [11C]raclopride was injected as an intravenous in the availability of phenylalanine and tyrosine for entry (i.v.) bolus and data were acquired for 60 min in time into the brain. Since the rate-limiting enzyme in catecho- frames of progressively longer duration. lamine synthesis, tyrosine hydroxylase, is normally incom- High-resolution (1 mm) T1-weighted magnetic resonance pletely saturated (Carlsson and Lindqvist, 1978), reduced (MR) images were obtained for all subjects (3D fast-field availability of the AA precursors decreases DA and NE echo scans with 160 slices, 1 mm isotropic resolution, synthesis. On both test days, subjects received a low oral TR ¼ 18 ms, TE ¼ 10 ms, flip angle ¼ 301). These volumes dose of d-amphetamine (0.3 mg/kg, p.o.). We recently were corrected for image intensity nonuniformity (Sled et al, reported that this dose of d-amphetamine decreases 1998), and linearly and nonlinearly transformed into [11C]raclopride binding potential (BP), and does so standardized stereotaxic space (Talairach and Tournoux, preferentially in the ventral striatum (Leyton et al, 2002). 1988) using automated feature matching to the MNI305 We predicted that APTD would attenuate the ability of d- template (Collins et al, 1994b; Collins and Evans, 1997). amphetamine to elicit DA release, as reflected by higher Each individual’s MRI was then coregistered to their [11C]raclopride BP values on the APTD vs BAL test day. summed radioactivity PET images (Evans et al, 1992). Inspection of the time activity curves suggested that one subject moved during one scan. Movement correction was METHODS made by applying an algorithm that corrects for between- Subjects frame misalignment due to head movement. This coregis- tration method realigns each PET frame to a ligand-specific, Eight healthy men (age, 23.1 7 3.6 years; weight, MRI-derived, four-dimensional template, which represents 72.1 7 10.9 kg) were recruited from advertisements placed radiotracer spatial distribution at each time point (Sechet in local newspapers and on campus. All were healthy et al, 2002; Reilhac et al, 2003). nonsmokers, as determined by a physical exam, standard PET images were reconstructed with a filtered back- laboratory tests, and an interview using the Structured projection using a 6 mm full-width half-maximum Hanning Clinical Interview for DSM-IV (First et al, 1995). None had a filter. Parametric images were generated by calculating 11 first-degree relative history of axis I psychiatric disorders as [ C]raclopride BP (BP ¼ BAvail/KD; BAvail ¼ density of avail- assessed by Research Diagnostic Criteria for Family able receptors) at each voxel, using a simplified reference Histories (Andreasen et al, 1977). On each day of the study, tissue compartmental model with cerebellar activity as the all tested negative on a urine drug screen sensitive to reference (Lammertsma and Hume, 1996; Gunn et al, 1997). cocaine, opiates, phencyclidine, barbiturates, D9-tetrahydro- T-maps were then constructed, representing t-tests of cannabinol, benzodiazepines, and amphetamines (Triaget change in [11C]raclopride BP between the two conditions; r Panel for Drugs of Abuse, Biosite Diagnostics , San Diego, the voxel-by-voxel comparisons assessed the same voxels CA, USA). The study was carried out in accordance with the for every subject (Aston et al, 2000). Clusters of statistically Declaration of Helsinki and was approved by the Montreal significant change were identified by thresholding the t-map Neurological Institute’s Research Ethics Board. at a value of tX4.2, which corresponds to po0.05 corrected for multiple comparisons and a search volume of the entire Procedure striatum (Worsley et al, 1996). BP values for each subject were extracted from the The day before each AA mixture test session, subjects ate a volume delineated by t-values greater than or equal to 4.2, low protein diet provided by the investigators, and fasted as well as from five anatomical regions of interest (ROI). from midnight. On the test day, subjects arrived at 0830 and Identifying the ROI entailed three steps. First, each tissue had blood samples drawn to measure plasma AA concen- type (gray matter, white matter, and CSF) was automatically trations. They then ingested one of the AA mixtures given in classified (Collins et al, 1998).
Recommended publications
  • Molecular Signatures of G-Protein-Coupled Receptors A
    REVIEW doi:10.1038/nature11896 Molecular signatures of G-protein-coupled receptors A. J. Venkatakrishnan1, Xavier Deupi2, Guillaume Lebon1,3,4,5, Christopher G. Tate1, Gebhard F. Schertler2,6 & M. Madan Babu1 G-protein-coupled receptors (GPCRs) are physiologically important membrane proteins that sense signalling molecules such as hormones and neurotransmitters, and are the targets of several prescribed drugs. Recent exciting developments are providing unprecedented insights into the structure and function of several medically important GPCRs. Here, through a systematic analysis of high-resolution GPCR structures, we uncover a conserved network of non-covalent contacts that defines the GPCR fold. Furthermore, our comparative analysis reveals characteristic features of ligand binding and conformational changes during receptor activation. A holistic understanding that integrates molecular and systems biology of GPCRs holds promise for new therapeutics and personalized medicine. ignal transduction is a fundamental biological process that is comprehensively, and in the process expand the current frontiers of required to maintain cellular homeostasis and to ensure coordi- GPCR biology. S nated cellular activity in all organisms. Membrane proteins at the In this analysis, we objectively compare known structures and reveal cell surface serve as the communication interface between the cell’s key similarities and differences among diverse GPCRs. We identify a external and internal environments. One of the largest and most diverse consensus structural scaffold of GPCRs that is constituted by a network membrane protein families is the GPCRs, which are encoded by more of non-covalent contacts between residues on the transmembrane (TM) than 800 genes in the human genome1. GPCRs function by detecting a helices.
    [Show full text]
  • Discovery of Small Molecule and Peptide-Based Ligands for the Methyl-Lysine Binding Proteins 53Bp1 and Phf1/Phf19
    DISCOVERY OF SMALL MOLECULE AND PEPTIDE-BASED LIGANDS FOR THE METHYL-LYSINE BINDING PROTEINS 53BP1 AND PHF1/PHF19 Michael Thomas Perfetti A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Division of Chemical Biology and Medicinal Chemistry in the Doctoral Program of the UNC Eshelman School of Pharmacy. Chapel Hill 2015 Approved by: Stephen Frye David Lawrence Albert Bowers Brian Strahl Greg Gang Wang Andrew Lee © 2015 Michael Thomas Perfetti ALL RIGHTS RESERVED ii ABSTRACT Michael Thomas Perfetti: Discovery of Small Molecule and Peptide-based Ligands for the Methyl-Lysine Binding Proteins 53BP1 and PHF1/PHF19 (Under the direction of Stephen V. Frye) Improving the understanding of the role of chromatin regulators in the initiation, development, and suppression of cancer and other devastating diseases is critical, as they are integral players in the regulation of DNA integrity and gene expression. Developing chemical tools for histone binding proteins that possess cellular activity will allow for further elucidation of the specific function of this class of histone regulating proteins. This research specifically targeted two different classes of Tudor domain containing histone binding proteins that are directly involved in the DNA damage response and modulation of gene transcription activities. The first methyl-lysine binding protein targeted was 53BP1, which is a DNA damage response protein. 53BP1 uses a tandem tudor domain (TTD) to recognize histone H4 dimethylated on lysine 20 (H4K20me2), a post-translational modification (PTM) induced by double-strand DNA breaks.
    [Show full text]
  • Synthesis of Isothiocyanates Using DMT/NMM/Tso− As a New Desulfurization Reagent
    molecules Article Synthesis of Isothiocyanates Using DMT/NMM/TsO− as a New Desulfurization Reagent Łukasz Janczewski 1,* , Dorota Kr˛egiel 2 and Beata Kolesi ´nska 1 1 Faculty of Chemistry, Institute of Organic Chemistry, Lodz University of Technology, Zeromskiego 116, 90-924 Lodz, Poland; [email protected] 2 Department of Environmental Biotechnology, Faculty of Biotechnology and Food Sciences, Lodz University of Technology, Wolczanska 171/173, 90-924 Lodz, Poland; [email protected] * Correspondence: [email protected] Abstract: Thirty-three alkyl and aryl isothiocyanates, as well as isothiocyanate derivatives from esters of coded amino acids and from esters of unnatural amino acids (6-aminocaproic, 4-(aminomethyl)benzoic, and tranexamic acids), were synthesized with satisfactory or very good yields (25–97%). Synthesis was performed in a “one-pot”, two-step procedure, in the presence of organic base (Et3N, DBU or NMM), and carbon disulfide via dithiocarbamates, with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4- methylmorpholinium toluene-4-sulfonate (DMT/NMM/TsO−) as a desulfurization reagent. For the synthesis of aliphatic and aromatic isothiocyanates, reactions were carried out in a microwave reactor, and selected alkyl isothiocyanates were also synthesized in aqueous medium with high yields (72–96%). Isothiocyanate derivatives of L- and D-amino acid methyl esters were synthesized, under conditions without microwave radiation assistance, with low racemization (er 99 > 1), and their absolute configuration was confirmed by circular dichroism. Isothiocyanate derivatives of natural and unnatural amino acids were evaluated for antibacterial activity on E. coli and S. aureus bacterial strains, where the Citation: Janczewski, Ł.; Kr˛egiel,D.; most active was ITC 9e.
    [Show full text]
  • The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 6-2020 The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting Robert J. Kohler Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Biological Psychology Commons Recommended Citation Kohler, Robert J., "The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting" (2020). Dissertations. 3565. https://scholarworks.wmich.edu/dissertations/3565 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING by Robert J. Kohler A dissertation submitted to the Graduate College In partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University June 2020 Doctoral Committee: Lisa Baker, Ph.D., Chair Anthony DeFulio, Ph.D. Cynthia Pietras, Ph.D. John Spitsbergen, Ph.D. Copyright by Robert J. Kohler 2020 THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING Robert J. Kohler, Ph.D. Western Michigan University, 2020 The resurgence of Lysergic Acid Diethylamide (LSD) as a therapeutic tool requires a revival in research, both basic and clinical, to bridge gaps in knowledge left from a previous generation of work. Currently, no study has been published with the intent of establishing optimal microdose concentrations of LSD in an animal model.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Last Decade of Unconventional Methodologies for the Synthesis Of
    Review molecules Last Decade of Unconventional Methodologies for theReview Synthesis of Substituted Benzofurans Last Decade of Unconventional Methodologies for the Lucia Chiummiento *, Rosarita D’Orsi, Maria Funicello and Paolo Lupattelli Synthesis of Substituted Benzofurans Department of Science, Via dell’Ateneo Lucano, 10, 85100 Potenza, Italy; [email protected] (R.D.); [email protected] (M.F.); [email protected] (P.L.) Lucia Chiummiento * , Rosarita D’Orsi, Maria Funicello and Paolo Lupattelli * Correspondence: [email protected] Department of Science, Via dell’Ateneo Lucano, 10, 85100 Potenza, Italy; [email protected] (R.D.); Academic Editor: Gianfranco Favi [email protected] (M.F.); [email protected] (P.L.) Received:* Correspondence: 22 April 2020; [email protected] Accepted: 13 May 2020; Published: 16 May 2020 Abstract:Academic This Editor: review Gianfranco describes Favi the progress of the last decade on the synthesis of substituted Received: 22 April 2020; Accepted: 13 May 2020; Published: 16 May 2020 benzofurans, which are useful scaffolds for the synthesis of numerous natural products and pharmaceuticals.Abstract: This In review particular, describes new the intramolecular progress of the and last decadeintermolecular on the synthesis C–C and/or of substituted C–O bond- formingbenzofurans, processes, which with aretransition-metal useful scaffolds catalysi for thes or synthesis metal-free of numerous are summarized. natural products(1) Introduction. and (2) Ringpharmaceuticals. generation via In particular, intramolecular new intramolecular cyclization. and (2.1) intermolecular C7a–O bond C–C formation: and/or C–O (route bond-forming a). (2.2) O– C2 bondprocesses, formation: with transition-metal (route b).
    [Show full text]
  • Specificity of the Antibody Receptor Site to D-Lysergamide
    Proc. Nat. Acad. Sci. USA Vol. 68, No. 7, pp. 1483-1487, July 1971 Specificity of the Antibody Receptor Site to D-Lysergamide: Model of a Physiological Receptor for Lysergic Acid Diethylamide (molecular structure/hallucinogenic/rabbit/guinea pig/psychotomimetic) HELEN VAN VUNAKIS, JOHN T. FARROW, HILDA B. GJIKA, AND LAWRENCE LEVINE Graduate Department of Biochemistry, Brandeis University, Waltham, Massachusetts 02154 Commnunicated by Francis 0. Schmitt, April 21, 1971 ABSTRACT Antibodies to D-lysergic acid have been amine, and NN-dimethyl-3,4,5-trimethoxyphenylethylamine produced in rabbits and guinea pigs and a radioimmuno- were the generous gifts of Dr. W. E. Scott of Hoffmann-La assay for the hapten was developed. The specificity of this Iysergamide-antilysergamide reaction was determined by Roche. DOM (2,5-dimethoxy-4-methylamphetamine) was competitive binding with unlabeled lysergic acid diethyl- given to us by Dr. S. H. Snyder of Johns Hopkins Univer- amnide (LSD), psychotomimetic drugs, neurotransmitters, sity. Sandoz Pharmaceuticals provided us with ergonovine, and other compounds with diverse structures. LSD and methylergonovine, ergosine, and ergotomine. LSD tartarate several related ergot alkaloids were potent competitors, three to seven times more potent than lysergic acid itself. powder (Sandoz Batch no. 98601) and psilocybin powder The NN-dimethyl derivatives of several compounds, in- (Sandoz Batch no. 55001) were provided by the U.S. Food and cluding tryptamine, 5-hydroxytryptamine, 4-hydroxy- Drug Administration and the National Institute of Mental tryptamine, 5-methoxytryptamine, tyramine, and mesca- Health. line, were only about ten times less effective than lysergic Psilocin was obtained by dephosphorylating psilocybin acid, even though these compounds lack some of the ring systems of lysergic acid.
    [Show full text]
  • Note N-Methyltyramine, a Gastrin-Releasing Factor in Beer, and Structurally Related Compounds As Agonists for Human Trace Amine-Associated Receptor 1
    _ Food Science and Technology Research, 26 (2), 313 317, 2020 Copyright © 2020, Japanese Society for Food Science and Technology http://www.jsfst.or.jp doi: 10.3136/fstr.26.313 Note N-Methyltyramine, a Gastrin-releasing Factor in Beer, and Structurally Related Compounds as Agonists for Human Trace Amine-associated Receptor 1 1,2* 1 1 1 3 3 Hiroto OHTA , Yuka MURAKAMI , Youhei TAKEBE , Kaori MURASAKI , Kenji OSHIMA , Hiroshi YOSHIHARA 1 and Shigeru MORIMURA 1Graduate School of Science and Technology, Kumamoto University, 2-39-1 Kurokami Chuo-ku, Kumamoto 860- 8555, Japan 2Department of Applied Microbial Technology, Faculty of Biotechnology and Life Science, Sojo University, 4-22-1 Ikeda Nishi-ku, Kumamoto 860-0082, Japan 3Department of Biological and Chemical Systems Engineering, National Institute of Technology, Kumamoto College, 2627 Hirayama-shinmachi, Yatsushiro, Kumamoto 866-8501, Japan Received September 30, 2019 ; Accepted December 5, 2019 N-Methyltyramine (N-MeTA) is known as a gastrin-releasing factor in beer. In this study, the agonistic actions of N-MeTA as well as tyramine (TA)/β-phenylethylamine (PEA) and their other N-methylated derivatives were examined to elucidate their structure-activity relationships, using a secreted placental alkaline phosphatase (SEAP)-based reporter assay in HEK-293 cells transiently expressing a G protein- coupled receptor, human trace amine-associated receptor 1 (hTAAR1). We detected the agonistic actions of six test compounds, including N-MeTA (EC50 = 6.78 µM), on hTAAR1. The agonistic actions were reduced depending on the number of N-methyl groups introduced into TA and PEA; the order of potency is PEA > N-methylphenylethylamine > TA ≈ N,N-dimethylphenylethylamine ≥ N-MeTA ≥ N,N-dimethyltyramine.
    [Show full text]
  • Cathinone-Derived Psychostimulants Steven J
    Review Cite This: ACS Chem. Neurosci. XXXX, XXX, XXX−XXX pubs.acs.org/chemneuro DARK Classics in Chemical Neuroscience: Cathinone-Derived Psychostimulants Steven J. Simmons,*,† Jonna M. Leyrer-Jackson,‡ Chicora F. Oliver,† Callum Hicks,† John W. Muschamp,† Scott M. Rawls,† and M. Foster Olive‡ † Center for Substance Abuse Research (CSAR), Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania 19140, United States ‡ Department of Psychology, Arizona State University, Tempe, Arizona 85281, United States ABSTRACT: Cathinone is a plant alkaloid found in khat leaves of perennial shrubs grown in East Africa. Similar to cocaine, cathinone elicits psychostimulant effects which are in part attributed to its amphetamine-like structure. Around 2010, home laboratories began altering the parent structure of cathinone to synthesize derivatives with mechanisms of action, potencies, and pharmacokinetics permitting high abuse potential and toxicity. These “synthetic cathinones” include 4-methylmethcathinone (mephedrone), 3,4-methylenedioxypyrovalerone (MDPV), and the empathogenic agent 3,4-methylenedioxymethcathinone (methylone) which collectively gained international popularity following aggressive online marketing as well as availability in various retail outlets. Case reports made clear the health risks associated with these agents and, in 2012, the Drug Enforcement Agency of the United States placed a series of synthetic cathinones on Schedule I under emergency order. Mechanistically, cathinone and synthetic derivatives work by augmenting monoamine transmission through release facilitation and/or presynaptic transport inhibition. Animal studies confirm the rewarding and reinforcing properties of synthetic cathinones by utilizing self-administration, place conditioning, and intracranial self-stimulation assays and additionally show persistent neuropathological features which demonstrate a clear need to better understand this class of drugs.
    [Show full text]
  • Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No
    Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No. Description Base Rate Staging 0101 Live horses, asses, mules and hinnies: 0101.10.00 -Purebred breeding animals Free E 0101.90 -Other: 0101.90.10 --Horses Free E 0101.90.20 --Asses 6.8% B --Mules and hinnies: 0101.90.30 ---Imported for immediate slaughter Free E 0101.90.40 ---Other 4.5% A 0102 Live bovine animals: 0102.10.00 -Purebred breeding animals Free E 0102.90 -Other: 0102.90.20 --Cows imported specially for dairy purposes Free E 0102.90.40 --Other 1 cent/kg A 0103 Live swine: 0103.10.00 -Purebred breeding animals Free E -Other: 0103.91.00 --Weighing less than 50 kg each Free E 0103.92.00 --Weighing 50 kg or more each Free E 0104 Live sheep and goats: 0104.10.00 -Sheep Free E 0104.20.00 -Goats 68 cents/head A 0105 Live poultry of the following kinds: Chickens, ducks, geese, turkeys and guineas: -Weighing not more than 185 g: 0105.11.00 --Chickens 0.9 cents each A 0105.12.00 --Turkeys 0.9 cents each A 0105.19.00 --Other 0.9 cents each A -Other: 0105.92.00 --Chickens, weighing not more than 2,000 g 2 cents/kg A 0105.93.00 --Chickens, weighing more than 2,000 g 2 cents/kg A 0105.99.00 --Other 2 cents/kg A 0106 Other live animals: -Mammals: 0106.11.00 --Primates Free E 0106.12.00 --Whales, dolphins and porpoises (mammals of the order Cetacea); manatees and dugongs (mammals of the order Sirenia) Free E 0106.19 --Other: 2B-Schedule-1 HTSUS No.
    [Show full text]
  • Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci
    (19) TZZ __T (11) EP 2 571 858 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 265/30 (2006.01) A61K 31/5375 (2006.01) 20.06.2018 Bulletin 2018/25 A61P 25/24 (2006.01) A61P 25/16 (2006.01) A61P 25/18 (2006.01) (21) Application number: 11723158.9 (86) International application number: (22) Date of filing: 20.05.2011 PCT/US2011/037361 (87) International publication number: WO 2011/146850 (24.11.2011 Gazette 2011/47) (54) PHENYLMORPHOLINES AND ANALOGUES THEREOF PHENYLMORPHOLINE UND ANALOGE DAVON PHENYLMORPHOLINES ET ANALOGUES DE CELLES-CI (84) Designated Contracting States: • DECKER, Ann Marie AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Durham, North Carolina 27713 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hoeger, Stellrecht & Partner Patentanwälte mbB (30) Priority: 21.05.2010 US 347259 P Uhlandstrasse 14c 70182 Stuttgart (DE) (43) Date of publication of application: 27.03.2013 Bulletin 2013/13 (56) References cited: WO-A1-2004/052372 WO-A1-2008/026046 (73) Proprietors: WO-A1-2008/087512 DE-B- 1 135 464 • Research Triangle Institute FR-A- 1 397 563 GB-A- 883 220 Research Triangle Park, North Carolina 27709 GB-A- 899 386 US-A1- 2005 267 096 (US) • United States of America, as represented by • R.A. GLENNON ET AL.: "Beta-Oxygenated The Secretary, Department of Health and Human Analogues of the 5-HT2A Serotonin Receptor Services Agonist Bethesda, Maryland 20892-7660 (US) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopro pane", JOURNAL OF MEDICINAL CHEMISTRY, (72) Inventors: vol.
    [Show full text]
  • Effects of Acute Tyrosine/Phenylalanine Depletion on the Selective Processing of Smoking-Related Cues and the Relative Value of Cigarettes in Smokers
    Psychopharmacology DOI 10.1007/s00213-007-0995-5 ORIGINAL INVESTIGATION Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers Brian Hitsman & James MacKillop & Anne Lingford-Hughes & Tim M. Williams & Faheem Ahmad & Sally Adams & David J. Nutt & Marcus R. Munafò Received: 16 May 2007 /Accepted: 18 October 2007 # Springer-Verlag 2007 Abstract tive mood, and expired carbon monoxide (CO) levels were Rationale Acute tyrosine/phenylalanine depletion (ATPD) is measured at various timepoints through 300 min. Participants a validated neurobiological challenge that results in reduced smoked at hourly intervals to prevent acute nicotine with- dopaminergic neurotransmission, allowing examination of drawal during testing. the effects of a hypodopaminergic state on craving-related Results The TYR/PHE-free mixture, as compared to the processes. BAL mixture, was associated with a greater increase in CO Objectives We studied 16 nonabstaining smokers (>10 levels from baseline ( p=0.01). Adjusting for the potential cigarettes/day; 9 males; age 20–33 years) to whom was confounding influence of between-condition differences in administered a tyrosine/phenylalanine-free mixture (TYR/ CO levels across time, TYR/PHE-free mixture was asso- PHE-free) and a balanced amino acid mixture (BAL) in a ciated with increased demand for cigarettes ( p=0.01) and double-blind, counterbalanced, crossover design. decreased attentional bias toward smoking-related words Methods Subjective cigarette craving, attentional bias to ( p=0.003). There were no significant differences between smoking-related word cues, relative value of cigarettes, nega- conditions in either subjective craving or depressed or anxious mood ( p values>0.05).
    [Show full text]